Rheumatoid Arthritis

The Skidki-na-vse® Rheumatoid Arthritis resource center provides clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.

What can we help you find?
New Treatment for Rheumatoid Arthritis Granted FDA Approval
Officials with the FDA have approved AbbVie’s upadacitinib (Rinvoq) 15 mg, once-daily oral Janus kinase (JAK) inhibitor, for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate (MTX-IR). 
FDA Approves Upadacitinib for Moderate-to-Severe Rheumatoid Arthritis
Upadacitinib (Rinvoq, AbbVie) is indicated for adults with moderate-to-severe rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate.
Patients with Rheumatoid Arthritis Achieve Low Disease Activity with Tofacitinib
Tofacitinib shows promising results in adult patients with moderately to severely active rheumatoid arthritis as a monotherapy with or without methotrexate.
Study: Statins Prevent Cardiovascular Events for Rheumatoid Arthritis
Research investigates whether statins are safe and effective for patients with inflammatory conditions, such as rheumatoid arthritis.
FDA: Elevated Risk of Blood Clots in Lungs, Death in RA Patients on Higher Dose Tofacitinib
A 10 mg twice daily dose of tofacitinib (Xeljanz, Xeljanz XR, Pfizer) used in patients with rheumatoid arthritis increased the risk of blood clots in the lungs and death in a safety clinical trial.
FDA Officials Report Increased Risk of Blood Clots in Lungs, Death with Higher Dose Tofacitinib
The higher dose is only approved for patients with ulcerative colitis, and not for RA.
Upadacitinib Granted Priority Review for Moderate-to-Severe Rheumatoid Arthritis
The New Drug Application for upadacitinib is supported by data from the phase 3 SELECT trial program evaluating patients with moderate-to-severe rheumatoid arthritis.
Rheumatoid Arthritis Biosimilar Meets Equivalency Endpoints in Phase 1/3 Trial
Rituximab is approved by the FDA for the treatment of adults with rheumatoid arthritis, non-Hodgkin's lymphoma, chronic lymphocytic leukemia, pemphigus vulgaris, granulomatosis with polyangiitis and microscopic polyangiitis.
FDA Approves New Autoinjector Formulation of Actemra
The single-dose, prefilled autoinjector for tocilizumab (Actemra) offers an additional option for patients with rheumatoid arthritis, giant cell arteritis, and 2 forms of juvenile arthritis.
Rheumatoid Arthritis Treatment Regimens Not Being Changed to Hit Low-Disease Activity Target
New data presented at the 2018 ACR/ARHP Annual Meeting shows that the treatment regimens for many patients are not being changed to reach a “treat-to-target” goal for low disease activity.
FDA OKs Sandoz's Biosimilar Adalimumab-adaz
Adalimumab-adaz (Hyrimoz), a biosimilar of Humira, is the third FDA-approved Sandoz biosimilar in the United States.
+ Load More